Dosage Forms

Stephanie Sutton was an assistant editor at Pharmaceutical Technology Europe.

Articles

Teva and Sun Pharmaceuticals? motion to overturn a verdict issued against them in April 2010 for patent infringement has been denied by a US court, leaving the companies at the mercy of pharma giants Pfizer and Nycomed, who have said they will "vigorously" pursue damage claims.

Pfizer and Nycomed sue generic firms

Teva's and Sun Pharmaceuticals' motion to overturn a verdict issued against them in April 2010 for patent infringement has been denied by a US court, leaving the companies at the mercy of pharma giants Pfizer and Nycomed, who have said they will "vigorously" pursue damage claims.

Nycomed and Pfizer Sue Generic Firms

States can reduce their Medicaid programs' healthcare expenditures by changing laws to enable generic drugs to be substituted for branded medications more easily and quickly, according to a new study conducted by CVS Caremark, a large pharmacy healthcare provider.

State Laws Affect Generic-Substitution Rates and Medicaid Costs, Says Study

Fifty percent of the marketing authorization applications for human medicines submitted to the European Medicines Agency (EMA) in 2009 were for generic and hybrid medicines &#151; 60% higher than the agency?s forecast.

Generic and hybrid applications 60% higher than estimates

Fifty percent of the marketing authorization applications for human medicines submitted to the European Medicines Agency (EMA) in 2009 were for generic and hybrid medicines?60% higher than the agency's forecast.

Generic and Hybrid Drug Applications 60% Higher than Estimates

In response to stringent price cuts introduced in Spain, the European Generics Association (EGA) is urging the Spanish government to adopt mechanisms that will help increase the dispensing of generic medicines.

Spain urged to double generic prescriptions

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

The traditional lines of demarcation between innovator-drug and generic-drug companies are blurring as each sector responds to changing industry fundamentals.

The Changing Business Models for Innovator-Drug and Generic-Drug Companies

Further consolidation, slowing growth in established markets, and growth in smaller and emerging markets are important factors influencing the direction of the global generic-drug market.

Seeking Opportunities in Generic Drugs

To best carry out the vision of Hatch-Waxman, Congress must act now on biogenerics.

Consumers Need Access to Lower-Cost Biogenerics

Analysis of the opportunities and challenges in the biosimilars market.